-25%

est. 2Y upside i

HealthcareSeries A

Labdoor is building the trusted online drugstore.

Rank

#2844

Sector

Consumer Health

Est. Liquidity

~5Y

Data Quality

Data: Low

Given the extreme preference overhang (513% of current valuation), negative expected returns (-25%), and stale entry mark, this equity is highly speculative with limited upside potential within a 2-year horizon.

Last updated: July 19, 2026

Bull (10%)+63%

If Labdoor achieves category leadership through brand trust and expands B2B testing services, revenue could grow faster and multiples expand to 4x forward revenue, yielding net upside of ~63% after 20% dilution.

Base (50%)+18%

With modest growth and multiple convergence to 3x (in line with testing comps), net upside is ~18% after dilution, though the stale valuation and preference overhang remain concerns.

Bear (40%)-100%

Given the massive preference stack ($8.2M vs $1.6M valuation) and weak revenue growth, any distressed exit leaves common stock worthless, resulting in a -100% return.

Est. time to liquidity~5.0 years

Preference Stack Risk

severe

Funding Intensity

51300%

Total funding of $8.21M far exceeds the $1.6M valuation, meaning common stock would be wiped out in any exit below $8.21M.

Dilution Risk

high

With only $532k revenue and no profitability, additional funding rounds are probable, further diluting common equity.

Secondary Liquidity

none

No secondary market activity detected; liquidity is unlikely in the near term.

Questions to Ask at the Interview

Strategic questions based on Labdoor's data — designed to show you've done your homework.

  • 1

    “How does Labdoor plan to scale revenue beyond affiliate marketing?”

  • 2

    “What is the path to profitability given low revenue and high operating costs?”

  • 3

    “How does the company plan to create liquidity for employees?”

Community

Valuation Sentiment

Our model estimates -25% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.